Ignite Creation Date:
2025-12-24 @ 7:07 PM
Ignite Modification Date:
2026-02-25 @ 4:58 PM
Study NCT ID:
NCT02586857
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-29
First Post:
2015-10-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Sponsor:
Acerta Pharma BV
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Glioblastoma Multiforme | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CLL | View |
| None | Chronic Lymphocytic Leukemia | View |
| None | NK | View |
| None | Natural Killer (Cells) | View |
| None | Glioblastoma Multiforme | View |
| None | GBM | View |
| None | Btk, | View |
| None | ORR | View |
| None | Overall Response Rate | View |
| None | OS | View |
| None | Overall Survival | View |
| None | RANO | View |
| None | Response Assessment in Neuro-oncology (Criteria) | View |
| None | RCI | View |
| None | Reliale Change Index (methodology) | View |